Press Room

Major investment in T1D research

JDRF Canada has made a major investment in accelerating type 1 diabetes research by awarding over $4M USD in grants to researchers across Canada.


Defymed Receives Support from JDRF to Fight Type 1 Diabetes

JDRF will contribute up to $500,000 in funds to finance preclinical studies on the MAILPAN® bioartificial pancreas


Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes

$2.45 million USD awarded to advance Sernova’s Cell Pouch System(TM) (CPS) technologies in a US FDA Clinical Trial with Initiation Scheduled for the Second Half of 2016


JDRF Honors Type 1 Diabetes Research Champions

JDRF presented three prestigious research awards to three experts whose groundbreaking research is accelerating life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications. 


JDRF and Sun Life Financial team up in the Revolution to Defeat Diabetes

The JDRF Revolution Ride to Defeat Diabetes, presented by Sun Life Financial, is taking place through September and October in 19 cities across Canada and will engage over 15,000 people who are ready to make a difference for those living with type 1 diabetes (T1D). 





JDRF-funded research points the way towards novel treatment for type 1 diabetes

JDRF Canada salutes the recent discovery of Dr. Pere Santamaria and his team who have identified a novel approach to halt and possibly reverse the autoimmune attack that triggers type 1 diabetes (T1D), causing the destruction of insulin-producing pancreatic beta cells in T1D patients. 


JDRF and Sanofi Announce Expansion of their Joint Research Collaboration to Include Development of Glucose Responsive Insulin Therapies for Treatment of Insulin-Dependent Diabetes

JDRF, the leading global organization funding and advocating for type 1 diabetes (T1D) research, and Sanofi US Services Inc., a subsidiary of Sanofi, one of the leading insulin manufacturers and a global pharmaceutical company, have entered into new agreements with four research organizations under ...


Lets turn type one into type none